SCHEMBL8738575

SCHEMBL8738575

CCC(C)(C)c1ccc2c(c1)OCO2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
CYP3A4 P08684 3/20 0.42
TAAR1 Q96RJ0 3/20 0.41
ATM Q13315 2/20 0.41
RAB9A P51151 2/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
CMA1 P23946 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP3 P42574 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GAA P10253 1/20 0.40
RECQL P46063 1/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8737899 0.89 ATM (0.45) MAPTATMRAB9ANPC1LMNA
SCHEMBL18649452 0.86 DRD3 (0.42) MAPTCYP3A4TAAR1ATMSLC6A2
SCHEMBL13368545 0.86 NPC1 (0.39) ATMRAB9ANPC1LMNAMAPK1
SCHEMBL12467359 0.85 MAPT (0.42) MAPTCYP3A4TAAR1ATMRAB9A
SCHEMBL20408458 0.84 RAB9A (0.38) MAPTATMRAB9ANPC1LMNA
SCHEMBL21346938 0.84 SHBG (0.44) MAPTCYP3A4TAAR1ATMRAB9A
SCHEMBL7407895 0.84 TAAR1 (0.47) MAPTCYP3A4TAAR1ATMRAB9A
SCHEMBL1746001 0.84 CYP3A4 (0.46) MAPTCYP3A4TAAR1RAB9ASLC6A2
SCHEMBL20408460 0.83 RAB9A (0.37) MAPTATMRAB9ANPC1LMNA
SCHEMBL9150315 0.82 CYP3A4 (0.44) MAPTCYP3A4TAAR1RAB9ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11591341-B2 Bicyclic and tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-02-28 US disclosed
US-20230035796-A1 CURCUMINOIDS, ANALOGS THEREOF, AND METHODS OF MAKING THE SAME WISYS TECHNOLOGY FOUNDATION, INC. 2023-02-02 US disclosed
US-20200361947-A1 BICYCLIC AND TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2020-11-19 US disclosed
US-20200317666-A1 HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2020-10-08 US disclosed
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) 2020-01-28 US disclosed
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME SALK INSTITUTE FOR BIOLOGICAL STUDIES 2019-09-19 US disclosed
US-20180210338-A1 RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN TOKYO OHKA KOGYO CO., LTD. (JP) 2018-07-26 US disclosed
US-9938259-B2 Therapeutic compositions and related methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-04-10 US disclosed
US-20170283401-A1 THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE AGIOS PHARMACEUTICALS, INC. 2017-10-05 US disclosed
US-9656955-B2 Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy ABBVIE INC. (US) 2017-05-23 US disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-8217029-B2 Oxazolidinone antibiotics ACTELION PHARMACEUTICALS LTD (CH) 2012-07-10 US disclosed
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS ACTELION PHARMACEUTICALS LTD (CH) 2011-02-17 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
US-20080113985-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2008-05-15 US disclosed
US-7312209-B2 Acridone inhibitors of IMPDH enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-25 US disclosed
US-20070264196-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-11-15 US disclosed
US-7285549-B2 Sulfamides and their use as endothelin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2007-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544134-B2 4-substituted coumarin derivatives and preparation methods and uses thereof MAP4, TUBA3C, ABCC1 MAPT 218/4885CYP3A4 52/4885TAAR1 4847/4885
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS HAVCR2, LIPC, HCCS MAPT 3566/4885CYP3A4 1503/4885TAAR1 4216/4885
US-20070264196-A1 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 MAPT 4347/4885CYP3A4 1769/4885TAAR1 3438/4885
US-20170283401-A1 THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE PDK2, PDK1, PDK3 MAPT 3834/4885CYP3A4 3797/4885TAAR1 4609/4885
US-20120130073-A1 INHIBITORS OF SYK AND JAK PROTEIN KINASES SYK, BTK, JAK1 MAPT 985/4885CYP3A4 617/4885TAAR1 3698/4885
US-20200361947-A1 BICYCLIC AND TRICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 MAPT 841/4885CYP3A4 48/4885TAAR1 2670/4885
US-20110039823-A1 OXAZOLIDINONE ANTIBIOTICS OXA1L, XDH, UBE2D3 MAPT 4178/4885CYP3A4 706/4885TAAR1 3262/4885
US-20230035796-A1 CURCUMINOIDS, ANALOGS THEREOF, AND METHODS OF MAKING THE SAME PTGES, ALOX5, ALOX15 MAPT 1912/4885CYP3A4 380/4885TAAR1 3278/4885
US-20080113985-A1 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 MAPT 4509/4885CYP3A4 1164/4885TAAR1 3137/4885
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 MAPT 2665/4885CYP3A4 2677/4885TAAR1 3844/4885
US-20190284207-A1 NOVEL ULK1 INHIBITORS AND METHODS USING SAME ULK1, ULK2, ULK3 MAPT 517/4885CYP3A4 4414/4885TAAR1 4717/4885
US-20200317666-A1 HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF IDO1, IDO2, INMT MAPT 3415/4885CYP3A4 716/4885TAAR1 342/4885
US-11591341-B2 Bicyclic and tricyclic compounds SLC10A1, PKD1, CYP11B2 MAPT 841/4885CYP3A4 48/4885TAAR1 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.